Xin Gao

13PUBLICATIONS
56CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Food properties (incl. characteristics and health benefits)Predictive and prognostic markersPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 12, 2026
FDA Approval Summary: Erdafitinib for FGFR3-Altered Locally Advanced or Metastatic Urothelial Carcinoma.

|Feb 12, 2026
FDA Approval Summary: Durvalumab for the Treatment of Adult Patients with Muscle-Invasive Bladder Cancer.

Nooshin Mirkheshti, Daniel Edem Kpormegbey, Chana Weinstock

|Aug 05, 2025
US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer.

Asma Dilawari, Hui Zhang, Mirat Shah

|May 19, 2025
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Mirat Shah, Ting-Yu Chen, Gwynn Ison

|Sep 09, 2024
FDA Approval Summary: Belzutifan for Patients with Advanced Renal Cell Carcinoma.

Jaleh Fallah, Brian L Heiss, Hee-Koung Joeng

|Sep 04, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma.

Michael H Brave, William F Maguire, Chana Weinstock

Pageof 3

Frequent Collaborators

12 joint publications

Laleh Amiri-Kordestani

12 joint publications

Richard Pazdur

8 joint publications

William Pierce

7 joint publications

Shenghui Tang